GETI.B

202

+0.65%↑

BIOAB

284.6

-2.47%↓

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

BIOAB

284.6

-2.47%↓

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

BIOAB

284.6

-2.47%↓

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

BIOAB

284.6

-2.47%↓

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

BIOAB

284.6

-2.47%↓

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

Search

Camurus AB

Cerrado

669 0.22

Resumen

Variación precio

24h

Actual

Mínimo

667.5

Máximo

669.5

Métricas clave

By Trading Economics

Ingresos

53M

292M

Ventas

117M

676M

P/B

Media del Sector

57.833

35.69

BPA

4.08

Margen de beneficio

43.235

Empleados

267

EBITDA

54M

315M

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

416M

41B

Apertura anterior

668.78

Cierre anterior

669

Camurus AB Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

26 sept 2025, 18:25 UTC

Principales Movimientos del Mercado

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 sept 2025, 07:00 UTC

Ganancias

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 sept 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept 2025, 20:54 UTC

Ganancias

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

26 sept 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 19:54 UTC

Charlas de Mercado

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept 2025, 19:53 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 19:40 UTC

Ganancias

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept 2025, 19:17 UTC

Charlas de Mercado

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept 2025, 19:15 UTC

Charlas de Mercado

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept 2025, 18:50 UTC

Charlas de Mercado
Ganancias

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept 2025, 18:36 UTC

Charlas de Mercado

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept 2025, 17:54 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept 2025, 16:56 UTC

Charlas de Mercado
Ganancias

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept 2025, 16:41 UTC

Charlas de Mercado
Ganancias

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept 2025, 16:26 UTC

Ganancias

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

26 sept 2025, 16:12 UTC

Charlas de Mercado

Nike Stock Seen With Limited Upside -- Market Talk

26 sept 2025, 15:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 sept 2025, 15:59 UTC

Charlas de Mercado

Nike Seen Showing Progress in Turnaround -- Market Talk

Comparación entre iguales

Cambio de precio

Camurus AB Esperado

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
help-icon Live chat